The 6th edition of the Kisaco Research international Phage Futures Europe will be held in Amsterdam, the Netherlands from Wednesday 6th July till Thursday 7th July 2022.
What is the 6th Phage Futures Europe and Why attend?
This year’s summit comes together to provide insights into the latest clinical updates from the global phage biotechnology companies and pioneering clinical therapeutic centers. The forum provides you with an opportunity to explore solutions to pressing challenges in the formulation, manufacturing, and regulation of phage products, driving forward clinical and commercial translation of phage technologies.
The 6th edition of the Phage Futures Europe introduces two days of an in-person conference, bringing together leading biopharma, expert academic centers, and innovative service providers to discuss and share research and development strategies for progressing bacteriophages’ past discovery. Examination of the microbiota as an effective phage target and developing strategic tools for the downstream production of phages. Discover the developments of leading biotechnology companies in the formulation of feed additives and the application of phages within agriculture.
This year’s conference will focus on; formulation and standardized trial design, optimizing manufacturing for stability and global market optimization, leading agriculture and poultry applications of phages, dedicated interactive panel to address specific challenges in the global regulatory landscape surrounding bacteriophages.
Countdown to Summit
Countdown to Summit
Who will be at the 6th Phage Futures Europe?
Over 20 speakers from a diversity of fields will be attending.
The summit will bring together individuals from different industries and occupations, such as; academia, biotech, pharma, regulatory and governments, service providers, and clinicians.
Agenda for the 6th Phage Futures Europe 2022
Wednesday 6th July 2022
Edith Hessel CSO at Eligo Bioscience – Expanding on the Precision Gene Editing Methods of Phage
Paul Garofolo CEO at Locus Bioscience – CRISPR-based precision medicine to treat UTIs
Merav Bassan CDO at Biomx – Application of Bacteriophages to Target the Microbiome
Alexander Sulakvelidze CSO at Intralytix – Bacteriophages for Modulating Human Microbiome: The PhageBiotix™ and SuperBiotix™ Approaches and Their Potential Applications
Kristin Wannerberger Director R&D Alliance Management at Ferring – Ferring and Phage
Sofia Corte-Real Scientific Advisor at Technophage – Phase I/IIa study of TP-102 bacteriophage treatment for diabetic foot infections targeting Pseudomonas aeruginosa
Nancy Tawil CSO at PhageLux – Strategies for the prolonged transdermal delivery of bacteriophage for the prevention and treatment of infected wounds
Lorenz Leitner Neuro-urologist at Balgrist University – Bacteriophages for catheter-associated urinary tract infections: Lessons learned from clinical trial
Danish Malik Biotechnology and Biomedical Engineering MSC Program Director at University of Loughborough – Manufacturing and Formulation Considerations for Phage Product Development
Jean-Paul Pirnay Head of Laboratory of Molecular and Cellular Technology at Queen Astrid Military Hospital – Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study
Gina Suh Infectious Disease Specialist at Mayo Clinic – Successful Case of Adjunctive Intravenous Bacteriophage Therapy to treat Left Ventricular Assist Device Infection
Ruby Lin Deputy Director of Phage Australia at The Westmead Institute – A Clinical Update on a Phase 2 Trial of The Application of Bacteriophages in Australia
Thursday 7th July 2022
Peter Beyer Senior Advisor at WHO, and Cara Fiore Microbiologist at FDA – Panel: Global Regulatory Evaluation on the Future of Phage
Tobi Nagel Founder & President of Phages for Global Health – The Global Economics of Bacteriophage Application
Olivia McAuliffe Principal Research Officer at Teagasc Food Research Centre – Bacteriophages as environmental decontamination agents in food production
Mimi Yen CEO at PhagePro – Phages for all: Using cholera prevention to establish phage infrastructure in resourcelimited settings
Christian Röhrig Head of Research and Development at Micreos – PhageGuard S in the treatment of Salmonella Species
Matthew Tebeau Chief Operating Officer at Proteon Pharmaceuticals – Bringing Phages (and Microbiome) into the Mainstream: Partnering on Product Development
Felipe Molina Professor at University of Extremadura – Computational design of minimum-sized phage cocktail: because less is more, isn’t it?
View past events by Kisaco Research